Morepen Labs Q1 FY27 Revenue Surges 34% YoY to ₹575 Cr; PAT Jumps 394%
Morepen Laboratories reported its highest-ever quarterly revenue of ₹575.31 crore in Q1 FY27, up 34% YoY. EBITDA surged 207% to ₹87.72 crore, and PAT jumped 394% to ₹56.35 crore. The company's ₹825 crore CDMO mandate entered full commercialization, with ₹58 crore in dispatches completed. Export revenue grew 111% YoY.
The announcement details record financial performance and significant growth across multiple business segments, including the successful commercialization of a major CDMO mandate. This indicates a strong positive impact on the company's financial health and future prospects.
The company reported record-breaking quarterly revenue and earnings, with significant year-on-year growth in revenue, EBITDA, and PAT. Key business segments like exports and CDMO showed strong performance, indicating a positive business outlook.
Morepen Laboratories Limited announced its financial results for the first quarter ended June 30, 2026, reporting its highest-ever quarterly revenue and earnings. The company's revenue stood at ₹575.31 crore, marking a 34% year-on-year increase. EBITDA grew by an impressive 207% YoY to ₹87.72 crore, with the EBITDA margin improving to 15.25% from 6.65% in Q1 FY26. Profit After Tax (PAT) surged by 394% YoY to ₹56.35 crore.
This strong performance was driven by several factors, including better operating leverage, improved performance in the Active Pharmaceutical Ingredients (API) segment, robust export growth, and the full-scale commercialization of its Contract Development and Manufacturing Organization (CDMO) mandate. Export revenue saw a significant jump of 111% YoY, while API business grew by 31% with API exports up 42%. The Medical Devices business also contributed positively, growing by 19%.
A key strategic milestone for the quarter was the entry of Morepen's previously announced ₹825 crore CDMO mandate into its full-scale commercialization phase. Commercial CDMO dispatches worth ₹58 crore were completed during Q1 FY27, validating the company's 'Morepen 2.0' strategy focused on innovation-led manufacturing and long-duration partnerships.
Mr. Sushil Suri, Chairman & Managing Director, highlighted the company's transformation journey, emphasizing the shift from a transaction-led API business to a manufacturing-led platform. He expressed confidence in Morepen's future growth, driven by disciplined execution, capacity expansion, customer diversification, and enhanced scientific and compliance capabilities.
Morepen's commitment to quality and regulatory compliance is underscored by its fourth consecutive USFDA inspection with zero Form 483 observations. To support future CDMO opportunities, the company plans to expand its manufacturing capacity up to 1,200 KL by FY30. The Medical Devices business, a second growth engine, focuses on chronic-care categories and has a substantial installed base for blood glucose meters and annual strip sales.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.